iRhythm Technologies’ Zio ambulatory cardiac monitors have the potential to change how doctors screen for atrial fibrillation and other arrythmias by combining miniaturized biosensors and data analytics into a wearable device, CEO Quentin Blackford explains to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Blackford sits down with BI analyst Matthew Henriksson for an in-depth interview to talk about iRhythm and how its systems allow patients to be monitored outside of medical offices without disrupting their everyday lives.
See omnystudio.com/listener for privacy information.
Vanguards of Health Care by Bloomberg Intelligence